Thomson Reuters' Big 3 segments hit 10% organic growth, but unresolved AI disruption risks temper optimism

What happened

Thomson Reuters' core Big 3 segments (Legal Professionals, Corporates, Tax & Accounting) achieved 10% organic growth in the latest reporting period, exceeding the company's full-year total organic growth guidance of 7.5-8% and underscoring their role as the primary revenue engine as recurring sales expand. This performance is consistent with the DeepValue master report's observation that these segments comprised roughly 80% of FY2025 revenues and had demonstrated strong momentum, with Q4 2025 organic growth of 9% in Legal and 11% in Tax. However, the new data does not directly address the two critical risks highlighted in that report: whether GenAI-enabled products can push ACV penetration beyond the 28% baseline, and whether competitive pricing pressure from AI-native challengers like Harvey and Clio+vLex is eroding renewal economics. While the robust subscription growth suggests resilience, the market's prior de-rating was driven by fears of AI disruption, and without evidence that GenAI attach is accelerating or discounting remains benign, valuation may still reflect significant uncertainty. Consequently, the 10% growth is a necessary but not sufficient condition to fully resolve the bear case, and investors should monitor upcoming disclosures on ACV mix and margin trajectory to confirm defensibility.

Implication

Investors should interpret the 10% organic growth in Big 3 as positive evidence that the subscription base remains sticky and that management's guidance may prove conservative, potentially supporting an upward revision to the base case value of $105. However, the market is likely to remain highly sensitive to any signs of competitive pricing pressure or slowing GenAI ACV penetration, as these were the primary drivers of the previous multiple compression. The next critical checkpoint will be the disclosure of GenAI-enabled products as a percentage of ACV for the latest quarter, which should show sequential improvement beyond 28% to confirm the AI monetization thesis. Additionally, investors should scrutinize the adjusted EBITDA margin for the Big 3 segments, as operating leverage is essential for free cash flow generation and supporting the dividend and buyback program. Until these data points are available, a prudent strategy is to hold existing positions with a bias to add on dips near the attractive entry level of $85, while maintaining a stop-loss if bear case indicators materialize.

Thesis delta

The new information indicates that the core business is performing at or above expectations, slightly increasing confidence in the base case scenario. However, the thesis remains conditional on AI monetization, and the article provides no evidence that GenAI ACV penetration or pricing power has improved. Therefore, the overall thesis is unchanged: a potential buy with conviction 4, pending confirmation from upcoming quarterly disclosures.